

Elizabeth E Powell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4214/publications.pdf>

Version: 2024-02-01

162
papers

14,504
citations

31976

53
h-index

19749

117
g-index

165
all docs

165
docs citations

165
times ranked

12636
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards collaborative management of non-alcoholic fatty liver disease: a "real-world" pathway for fibrosis risk assessment in primary care. <i>Internal Medicine Journal</i> , 2022, 52, 1749-1758.	0.8	3
2	Predicting Liver-Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests. <i>Hepatology Communications</i> , 2022, 6, 728-739.	4.3	20
3	An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care. <i>Diabetic Medicine</i> , 2022, 39, e14799.	2.3	8
4	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 1030-1041.	3.7	74
5	Therapeutic potential of macrophage colony-stimulating factor in chronic liver disease. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	2.4	7
6	The temporal pattern and lifestyle associations of respiratory virus infection in a cohort study spanning the first two years of life. <i>BMC Pediatrics</i> , 2022, 22, 166.	1.7	3
7	Disruption of the circadian clock component BMAL1 elicits an endocrine adaption impacting on insulin sensitivity and liver disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200083119.	7.1	44
8	Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes. <i>BMC Health Services Research</i> , 2022, 22, 487.	2.2	2
9	The Impact of Social Workers in Cirrhosis Care: a Systematic Review. <i>Current Treatment Options in Gastroenterology</i> , 2022, 20, 160-176.	0.8	3
10	Partnering with support persons and clinicians to improve the health care experiences of patients with cirrhosis. <i>Journal of Clinical Nursing</i> , 2022, , .	3.0	1
11	Patient-oriented medication education intervention has long-term benefits for people with decompensated cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 3281-3282.	4.3	1
12	Epidemiology of ascites fluid infections in patients with cirrhosis in Queensland, Australia from 2008 to 2017. <i>Medicine (United States)</i> , 2022, 101, e29217.	1.0	3
13	Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosis. <i>Journal of Hepatology</i> , 2022, 77, 1219-1221.	3.7	6
14	Poor disease knowledge is associated with higher healthcare service use and costs among patients with cirrhosis: an exploratory study. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	9
15	Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 873-884.	2.8	16
16	Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis. <i>Internal Medicine Journal</i> , 2021, 51, 691-698.	0.8	13
17	The Patient's Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age. <i>Hepatology Communications</i> , 2021, 5, 891-905.	4.3	8
18	Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000572.	2.7	19

#	ARTICLE	IF	CITATIONS
19	Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2021, 11, 2858.	3.3	16
20	Non-alcoholic fatty liver disease: raising awareness of a looming public health problem. <i>Medical Journal of Australia</i> , 2021, 215, 75-76.	1.7	0
21	Non-alcoholic fatty liver disease. <i>Lancet, The</i> , 2021, 397, 2212-2224.	13.7	1,035
22	Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia. <i>EClinicalMedicine</i> , 2021, 36, 100919.	7.1	14
23	Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety. <i>Pharmaceuticals</i> , 2021, 14, 1207.	3.8	1
24	Disparities in Unmet Needs in Indigenous and Non-Indigenous Australians with Cirrhosis: An Exploratory Study. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2649-2658.	1.8	3
25	Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000695.	2.7	6
26	ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000485.	2.7	21
27	Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis. <i>Internal Medicine Journal</i> , 2020, 50, 1142-1146.	0.8	10
28	Nonalcoholic fatty liver disease burden: Australia, 2019-2030. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1628-1635.	2.8	68
29	Type 2 Diabetes: A Risk Factor for Hospital Readmissions and Mortality in Australian Patients With Cirrhosis. <i>Hepatology Communications</i> , 2020, 4, 1279-1292.	4.3	15
30	Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology Clinics. <i>Hepatology Communications</i> , 2020, 4, 518-526.	4.3	12
31	Hospitalisation for cirrhosis in Australia: disparities in presentation and outcomes for Indigenous Australians. <i>International Journal for Equity in Health</i> , 2020, 19, 27.	3.5	14
32	Protocol for a randomised trial testing a community fibrosis assessment service for patients with suspected non-alcoholic fatty liver disease: LOCAl assessment and triage evaluation of non-alcoholic fatty liver disease (LOCATE-NAFLD). <i>BMC Health Services Research</i> , 2020, 20, 335.	2.2	4
33	Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC). <i>Patient Preference and Adherence</i> , 2020, Volume 14, 599-611.	1.8	18
34	Weight-based tacrolimus trough concentrations post liver transplant. <i>Internal Medicine Journal</i> , 2019, 49, 79-83.	0.8	3
35	Contemporary Educational Interventions for General Practitioners (GPs) in Primary Care Settings in Australia: A Systematic Literature Review. <i>Frontiers in Public Health</i> , 2019, 7, 176.	2.7	9
36	Reply. <i>Hepatology Communications</i> , 2019, 3, 1283-1284.	4.3	0

#	ARTICLE	IF	CITATIONS
37	Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic type 2 inflammation. <i>British Journal of Pharmacology</i> , 2019, 176, 3775-3790.	5.4	21
38	Engaging primary care clinicians in the assessment of NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 458-460.	17.8	5
39	Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	91
40	Increasing Hospitalization Rates for Cirrhosis: Overrepresentation of Disadvantaged Australians. <i>EClinicalMedicine</i> , 2019, 11, 44-53.	7.1	39
41	Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention. <i>Hepatology Communications</i> , 2019, 3, 620-631.	4.3	33
42	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- β 1 dependent mechanisms. <i>Scientific Reports</i> , 2019, 9, 1439.	3.3	7
43	Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 293.	4.8	116
44	Haemochromatosis: a clinical update for the practising physician. <i>Internal Medicine Journal</i> , 2018, 48, 509-516.	0.8	26
45	Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. <i>Internal Medicine Journal</i> , 2018, 48, 144-151.	0.8	80
46	Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 80-94.	3.4	30
47	A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care. <i>Hepatology Communications</i> , 2018, 2, 897-909.	4.3	54
48	Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 799-804.	2.3	10
49	Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. <i>JCI Insight</i> , 2018, 3, .	5.0	35
50	Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia. <i>Internal Medicine Journal</i> , 2017, 47, 429-435.	0.8	21
51	IFN- γ 3, not IFN- γ 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017, 49, 795-800.	21.4	86
52	Identifying areas of need relative to liver disease: geographic clustering within a health service district. <i>Australian Health Review</i> , 2017, 41, 407.	1.1	3
53	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089.	1.3	174
54	Optimising care of patients with chronic disease: patient-oriented education may improve disease knowledge and self-management. <i>Internal Medicine Journal</i> , 2017, 47, 952-955.	0.8	23

#	ARTICLE	IF	CITATIONS
55	Multimorbidity and polypharmacy in diabetic patients with NAFLD. <i>Medicine (United States)</i> , 2017, 96, e6761.	1.0	39
56	The toll-like receptor 3 pathway in homeostasis, responses to injury and wound repair. <i>Seminars in Cell and Developmental Biology</i> , 2017, 61, 22-30.	5.0	39
57	Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-8.	1.9	17
58	Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 339.	1.6	12
59	Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , 2017, 23, 7321-7331.	3.3	25
60	Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers. <i>PLoS ONE</i> , 2016, 11, e0167001.	2.5	29
61	Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 68-77.	3.7	9
62	Patterns of service utilisation within Australian hepatology clinics: high prevalence of advanced liver disease. <i>Internal Medicine Journal</i> , 2016, 46, 420-426.	0.8	12
63	Can paracetamol (acetaminophen) be administered to patients with liver impairment?. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 210-222.	2.4	69
64	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , 2016, 7, 12757.	12.8	104
65	Prevalence of medication discrepancies in patients with cirrhosis: a pilot study. <i>BMC Gastroenterology</i> , 2016, 16, 114.	2.0	25
66	The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. <i>Liver International</i> , 2016, 36, 370-377.	3.9	51
67	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016, 64, 34-46.	7.3	83
68	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016, 64, 390-398.	3.7	64
69	Spatiotemporal Characterization of the Cellular and Molecular Contributors to Liver Fibrosis in a Murine Hepatotoxic-Injury Model. <i>American Journal of Pathology</i> , 2016, 186, 524-538.	3.8	28
70	CRIg-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites. <i>JCI Insight</i> , 2016, 1, e86914.	5.0	53
71	Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation. <i>PLoS ONE</i> , 2016, 11, e0157771.	2.5	33
72	Deletion of Wntless in myeloid cells exacerbates liver fibrosis and the ductular reaction in chronic liver injury. <i>Fibrogenesis and Tissue Repair</i> , 2015, 8, 19.	3.4	36

#	ARTICLE	IF	CITATIONS
73	<sc>ELF</sc> score ≥ 9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity. Liver International, 2015, 35, 1673-1681.	3.9	60
74	Response to ELF cut-off points: aetiology is also a relevant factor. Liver International, 2015, 35, 1921-1921.	3.9	0
75	Ascites Bacterial Burden and Immune Cell Profile Are Associated with Poor Clinical Outcomes in the Absence of Overt Infection. PLoS ONE, 2015, 10, e0120642.	2.5	38
76	Interferon- γ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature Communications, 2015, 6, 6422.	12.8	156
77	Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. BMJ Open, 2015, 5, e007451-e007451.	1.9	59
78	Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change?. Internal Medicine Journal, 2014, 44, 865-872.	0.8	47
79	The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology, 2014, 59, 1393-1405.	7.3	344
80	New Paradigms in the Histopathology of NAFLD. Current Hepatology Reports, 2014, 13, 81-87.	0.9	0
81	Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers. BMC Gastroenterology, 2014, 14, 97.	2.0	37
82	Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration. World Journal of Gastroenterology, 2014, 20, 17851-17862.	3.3	57
83	Portal, but not lobular, macrophages express matrix metalloproteinase-9: association with the ductular reaction and fibrosis in chronic hepatitis C. Liver International, 2013, 33, 569-579.	3.9	42
84	CCR5- $\Delta 32$ genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes and Immunity, 2013, 14, 286-290.	4.1	5
85	Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. Internal Medicine Journal, 2013, 43, 247-253.	0.8	55
86	Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver International, 2013, 33, 624-632.	3.9	48
87	<sc>BMI</sc> But Not Stage or Etiology of Nonalcoholic Liver Disease Affects the Diagnostic Utility of Carbohydrate-Deficient Transferrin. Alcoholism: Clinical and Experimental Research, 2013, 37, 1771-1778.	2.4	6
88	Assessment of alcohol histories obtained from patients with liver disease: opportunities to improve early intervention. Internal Medicine Journal, 2013, 43, 1096-1102.	0.8	7
89	Use of standardised assessment forms in referrals to hepatology outpatient services: implications for accurate triaging of patients with chronic hepatitis C. Australian Health Review, 2013, 37, 218.	1.1	12
90	Khat-associated hepatitis. Medical Journal of Australia, 2013, 199, 498-499.	1.7	11

#	ARTICLE	IF	CITATIONS
91	Triage of referrals to outpatient hepatology services: an ineffective tool to prioritise patients?. Australian Health Review, 2012, 36, 443.	1.1	2
92	Liver repercussions of defective gut surveillance. Hepatology, 2012, 56, 1174-1177.	7.3	2
93	Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. Gastroenterology, 2012, 143, 1244-1252.e12.	1.3	142
94	Macrophage secretory products induce an inflammatory phenotype in hepatocytes. World Journal of Gastroenterology, 2012, 18, 1732.	3.3	32
95	GH-Dependent STAT5 Signaling Plays an Important Role in Hepatic Lipid Metabolism. Endocrinology, 2011, 152, 181-192.	2.8	155
96	Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Medicine, 2011, 3, 57.	8.2	62
97	No evidence of the unfolded protein response in patients with chronic hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 319-327.	2.8	16
98	Interleukin-32: A new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. Hepatology, 2011, 53, 1819-1829.	7.3	79
99	Not every cell is as it seems: a role for ductular epithelial cells in fibrosis?. Gut, 2011, 60, 1-2.	12.1	3
100	IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. PLoS Medicine, 2011, 8, e1001092.	8.4	107
101	Metabolic Factors and Non-Alcoholic Fatty Liver Disease as Co-Factors in Other Liver Diseases. Digestive Diseases, 2010, 28, 186-191.	1.9	43
102	Kupffer cells and hepatocyte metabolism: A two-way street?. Hepatology, 2009, 49, 690-692.	7.3	3
103	Hepatic progenitor cell-mediated regeneration and fibrosis: Chicken or egg?. Hepatology, 2009, 49, 1424-1426.	7.3	27
104	IL28B is associated with response to chronic hepatitis C interferon- α and ribavirin therapy. Nature Genetics, 2009, 41, 1100-1104.	21.4	1,808
105	Combined approach for non-invasive measurement of liver pathology by MR. Journal of Hepatology, 2009, 51, 1083-1084.	3.7	1
106	Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. Journal of Hepatology, 2009, 51, 389-397.	3.7	156
107	Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. Journal of Magnetic Resonance Imaging, 2008, 28, 937-945.	3.4	174
108	Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology, 2008, 48, 80-87.	7.3	64

#	ARTICLE	IF	CITATIONS
109	Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. <i>Journal of Hepatology</i> , 2008, 49, 1046-1054.	3.7	46
110	Recognition of Genetic Factors Influencing the Progression of Hepatitis C. <i>Molecular Diagnosis and Therapy</i> , 2008, 12, 209-218.	3.8	18
111	Steatosis as a Cofactor in Other Liver Diseases: Hepatitis C Virus, Alcohol, Hemochromatosis, and Others. <i>Clinics in Liver Disease</i> , 2007, 11, 173-189.	2.1	44
112	Progressive Fibrosis in Nonalcoholic Steatohepatitis: Association With Altered Regeneration and a Ductular Reaction. <i>Gastroenterology</i> , 2007, 133, 80-90.	1.3	425
113	Obesity management in liver clinics: Translation of research into clinical practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 504-509.	2.8	25
114	Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data. <i>Gastroenterology</i> , 2006, 130, 1636-1642.	1.3	517
115	Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. <i>Gut</i> , 2006, 55, 529-535.	12.1	251
116	Fibrosis correlates with a ductular reaction in hepatitis C: Roles of impaired replication, progenitor cells and steatosis. <i>Hepatology</i> , 2005, 41, 809-818.	7.3	322
117	Steatosis: Co-factor in other liver diseases. <i>Hepatology</i> , 2005, 42, 5-13.	7.3	347
118	A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. <i>Journal of Medical Genetics</i> , 2005, 42, e45-e45.	3.2	44
119	Adiponectin and its receptors in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 929-936.	3.7	90
120	Steatosis Is a Cofactor in Liver Injury in Hemochromatosis. <i>Gastroenterology</i> , 2005, 129, 1937-1943.	1.3	158
121	Dangerous Liaisons: The Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. <i>Annals of Internal Medicine</i> , 2005, 143, 753.	3.9	22
122	Nonalcoholic fatty liver disease: is all the fat bad?. <i>Internal Medicine Journal</i> , 2004, 34, 187-191.	0.8	37
123	CCR5-Δ32 mutation is strongly associated with primary sclerosing cholangitis. <i>Genes and Immunity</i> , 2004, 5, 444-450.	4.1	66
124	Chronic hepatitis C and steatosis. <i>Current Hepatitis Reports</i> , 2004, 3, 123-128.	0.3	21
125	Virus-specific CD8+ T lymphocytes within the normal human liver. <i>European Journal of Immunology</i> , 2004, 34, 1526-1531.	2.9	30
126	Steatosis and liver cell apoptosis in chronic hepatitis C: A mechanism for increased liver injury. <i>Hepatology</i> , 2004, 39, 1230-1238.	7.3	133

#	ARTICLE	IF	CITATIONS
127	Increased mononuclear cell activation and apoptosis early after human liver transplantation is associated with a reduced frequency of acute rejection. <i>Liver Transplantation</i> , 2004, 10, 397-403.	2.4	5
128	Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. <i>Gut</i> , 2004, 53, 413-419.	12.1	382
129	Association Between Apolipoprotein E ϵ 4 and Neuropsychiatric Symptoms During Interferon α Treatment for Chronic Hepatitis C. <i>Psychosomatics</i> , 2004, 45, 49-57.	2.5	35
130	Steatosis in chronic hepatitis C: Association with increased messenger RNA expression of collagen I, tumor necrosis factor α and cytochrome P450 ω 2E1. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 386-392.	2.8	72
131	Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. <i>Journal of Hepatology</i> , 2003, 39, 967-971.	3.7	85
132	In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. <i>Journal of Hepatology</i> , 2003, 39, 1042-1048.	3.7	157
133	Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. <i>International Journal of Epidemiology</i> , 2003, 32, 717-724.	1.9	129
134	Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. <i>Gut</i> , 2002, 51, 89-94.	12.1	259
135	Lymphocyte apoptosis and cell replacement in human liver allografts. <i>Transplantation</i> , 2002, 73, 1828-1834.	1.0	16
136	Fibrosis in chronic hepatitis C correlates significantly with circulating insulin levels. <i>Journal of Hepatology</i> , 2002, 36, 172.	3.7	2
137	Intensive dietary intervention improves weight maintenance in the management of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2002, 36, 256.	3.7	2
138	Low-titre auto-antibodies predict autoimmune disease during interferon α treatment of chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 419-422.	2.8	47
139	Interaction of non-alcoholic fatty liver disease with other liver diseases. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2002, 16, 767-781.	2.4	47
140	Angiotensin-Converting Enzyme Inhibition Attenuates the Progression of Rat Hepatic Fibrosis. <i>Gastroenterology</i> , 2001, 121, 148-155.	1.3	276
141	Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. <i>Journal of Hepatology</i> , 2001, 34, 314-320.	3.7	133
142	Role of cytokine gene polymorphisms in acute rejection and renal impairment after liver transplantation. <i>Liver Transplantation</i> , 2001, 7, 255-263.	2.4	28
143	Host genetic factors influence disease progression in chronic hepatitis C. <i>Hepatology</i> , 2000, 31, 828-833.	7.3	369
144	Detection of male DNA in the liver of female patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2000, 33, 690-695.	3.7	86

#	ARTICLE	IF	CITATIONS
145	Expression of cytokines and factors modulating apoptosis by human sinusoidal leucocytes. <i>Journal of Hepatology</i> , 2000, 32, 392-398.	3.7	16
146	CASE REPORT: Lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999, 14, 801-803.	2.8	27
147	Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. <i>Hepatology</i> , 1999, 29, 1215-1219.	7.3	623
148	Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. <i>Hepatology</i> , 1999, 30, 526-530.	7.3	389
149	ROLE OF DONOR LEUKOCYTE CHIMERISM IN ESTABLISHING THE ETIOLOGY OF NEUTROPENIA AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 1999, 67, 1358-1361.	1.0	6
150	Serum Soluble CD23 but Not IL8, IL10, GM-CSF, or IFN- γ Is Elevated in Patients with Hepatitis C Infection. <i>Clinical Immunology and Immunopathology</i> , 1997, 84, 139-144.	2.0	20
151	Peripheral blood chimerism following human liver transplantation. <i>Hepatology</i> , 1997, 25, 1233-1236.	7.3	55
152	Detection of circulating donor deoxyribonucleic acid by microsatellite analysis in a liver transplant recipient. <i>Liver Transplantation</i> , 1996, 2, 391-394.	1.8	20
153	Successful in vitro fertilization and pregnancy in a patient with autoimmune chronic active hepatitis and cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1995, 10, 233-235.	2.8	9
154	Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in human liver. <i>Journal of Clinical Investigation</i> , 1994, 93, 2168-2174.	8.2	82
155	Liver, lipoproteins and disease: I. Biochemistry of lipoprotein metabolism. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1992, 7, 214-224.	2.8	10
156	Liver, lipoproteins and disease: II. Clinical relevance of disordered cholesterol metabolism in liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1992, 7, 225-231.	2.8	7
157	Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: An aid to diagnosis. <i>Hepatology</i> , 1991, 13, 455-459.	7.3	59
158	Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: An aid to diagnosis. <i>Hepatology</i> , 1991, 13, 455-459.	7.3	9
159	Improvement in chronic hepatocerebral degeneration following liver transplantation. <i>Gastroenterology</i> , 1990, 98, 1079-1082.	1.3	88
160	The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. <i>Hepatology</i> , 1990, 11, 74-80.	7.3	1,354
161	Steatohepatitis associated with limb lipodystrophy. <i>Gastroenterology</i> , 1989, 97, 1022-1024.	1.3	72
162	Differences in the pattern and cost of hospital care between Indigenous and non-Indigenous Australians with cirrhosis: an exploratory study. <i>Internal Medicine Journal</i> , 0, , .	0.8	0